|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNX15 |
Gene summary for SNX15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNX15 | Gene ID | 29907 |
| Gene name | sorting nexin 15 | |
| Gene Alias | HSAF001435 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | E5KQS5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29907 | SNX15 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.44e-05 | 1.62e-01 | -0.1808 |
| 29907 | SNX15 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.67e-02 | 1.27e-01 | -0.0811 |
| 29907 | SNX15 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.38e-10 | 2.49e-01 | -0.1088 |
| 29907 | SNX15 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.00e-27 | 4.68e-01 | -0.1954 |
| 29907 | SNX15 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 2.94e-01 | -0.2602 |
| 29907 | SNX15 | HTA11_3361_2000001011 | Human | Colorectum | AD | 7.91e-05 | 2.13e-01 | -0.1207 |
| 29907 | SNX15 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.73e-04 | 2.58e-01 | -0.1526 |
| 29907 | SNX15 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.44e-12 | 2.36e-01 | -0.1464 |
| 29907 | SNX15 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.52e-13 | 2.52e-01 | -0.1001 |
| 29907 | SNX15 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.17e-15 | 3.32e-01 | -0.059 |
| 29907 | SNX15 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.72e-05 | 3.10e-01 | -0.1706 |
| 29907 | SNX15 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.03e-03 | 1.93e-01 | -0.2061 |
| 29907 | SNX15 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.34e-04 | 3.36e-01 | -0.1462 |
| 29907 | SNX15 | HTA11_546_2000001011 | Human | Colorectum | AD | 8.71e-06 | 2.90e-01 | -0.0842 |
| 29907 | SNX15 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.84e-09 | 2.28e-01 | 0.096 |
| 29907 | SNX15 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.40e-02 | 1.93e-01 | 0.0446 |
| 29907 | SNX15 | HTA11_8622_2000001021 | Human | Colorectum | SER | 8.37e-05 | 2.26e-01 | 0.0528 |
| 29907 | SNX15 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.21e-02 | 2.06e-01 | 0.0171 |
| 29907 | SNX15 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.05e-06 | 1.48e-01 | 0.0674 |
| 29907 | SNX15 | HTA11_7469_2000001011 | Human | Colorectum | AD | 2.39e-03 | 2.90e-01 | -0.0124 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNX15 | SNV | Missense_Mutation | novel | c.265N>A | p.Glu89Lys | p.E89K | Q9NRS6 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SNX15 | SNV | Missense_Mutation | c.559N>C | p.Asp187His | p.D187H | Q9NRS6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| SNX15 | SNV | Missense_Mutation | c.654C>A | p.Phe218Leu | p.F218L | Q9NRS6 | protein_coding | tolerated(0.31) | benign(0.036) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SNX15 | SNV | Missense_Mutation | rs530595640 | c.212G>A | p.Arg71His | p.R71H | Q9NRS6 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| SNX15 | SNV | Missense_Mutation | novel | c.602C>T | p.Ser201Phe | p.S201F | Q9NRS6 | protein_coding | tolerated(0.3) | benign(0.275) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| SNX15 | SNV | Missense_Mutation | c.1015N>G | p.Gln339Glu | p.Q339E | Q9NRS6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SNX15 | SNV | Missense_Mutation | rs200424255 | c.200N>A | p.Arg67His | p.R67H | Q9NRS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3502-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SNX15 | SNV | Missense_Mutation | c.290N>A | p.Arg97Gln | p.R97Q | Q9NRS6 | protein_coding | deleterious(0) | benign(0.114) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNX15 | SNV | Missense_Mutation | novel | c.986N>A | p.Ala329Glu | p.A329E | Q9NRS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SNX15 | SNV | Missense_Mutation | c.158N>A | p.Ser53Asn | p.S53N | Q9NRS6 | protein_coding | deleterious(0.01) | benign(0.426) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |